Colorectal Cancer | Specialty

The OncLive Colorectal Cancer condition center page is a comprehensive resource for clinical news and expert insights on colorectal cancer treatment and management, with a focus on novel therapeutic strategies including checkpoint inhibitors and TKIs across lines of therapy. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in colorectal cancer.

Dr. Sears on Bacteria Influencing Development of Colon Cancer

February 7th 2017

Cynthia L. Sears, MD, professor of Medicine, Johns Hopkins University School of Medicine, member of the Bloomberg-Kimmel Institute for Cancer Immunotherapy, discusses bacteria possibly influencing the development of colon cancer.

Enhanced Recovery Program Improves Outcomes After Colorectal Cancer Surgery

February 3rd 2017

The adoption of enhanced recovery after surgery protocols can improve not only the outcomes of patients after a procedure but can also reduce hospital costs, as has been seen in an ERAS program in colorectal cancer at the University of Virginia Health System.

Dr. Muro Discusses Safety Data from Asian XELIRI Project in CRC

February 2nd 2017

Kei Muro, MD, Aichi Cancer Center Hospital, discusses the findings of Asian XELIRI project (AXEPT) in colorectal cancer (CRC).

S-1 Better Tolerated Than Capecitabine With No Loss of Efficacy in Metastatic Colorectal Cancer

February 2nd 2017

The incidence of hand-foot syndrome was decreased following first-line treatment with S-1 compared to capecitabine in patients with metastatic colorectal cancer, according to findings from the phase III SALTO study that were presented at the 2017 European Cancer Congress.

Treatment, Diagnosis Disparities Among Hospitals Impacts Survival of Patients With Colorectal Cancer and Peritoneal Metastases

February 1st 2017

Patients receiving the same diagnosis, colorectal cancer with synchronous peritoneal metastases, were offered different treatments that led to dramatically different outcomes based upon the institution in which they were diagnosed. Findings presented at the 19th European Cancer Congress revealed underutilization of a highly effective treatment, due to a lack of referral.

Dr. Marshall on Molecular Variances Between Right- Versus Left-Sided Colon Cancer

January 30th 2017

John L. Marshall, MD, chief, Division of Hematology/Oncology, Medstar Georgetown University Hospital, associate director, Clinical Research, Lombardi Comprehensive Cancer Center at Georgetown University Hospital, discusses molecular variances between right- and left-sided colon cancer.

Dr. Sears on Microbiota in Colon Cancer

January 28th 2017

Cynthia L. Sears, MD, professor of Medicine, at John Hopkins University School of Medicine, member of the Bloomberg-Kimmel Institute for Cancer Immunotherapy, discusses microbiota in patients with colon cancer.

Vemurafenib Adds to PFS in BRAF-mutant mCRC

January 25th 2017

Adding vemurafenib to the routinely employed combination of irinotecan and cetuximab prolonged progression-free survival in patients with BRAF-mutant metastatic colorectal cancer.

Dr. Loaiza-Bonilla on Right- Versus Left-Sided Colorectal Cancer

January 24th 2017

Arturo Loaiza-Bonilla, MD, medical oncologist, specialized in gastrointestinal malignancies, assistant professor of Clinical Medicine at the University of Pennsylvania, discusses findings of patients with right- versus left-sided tumors of colorectal cancer (CRC).

Nivolumab Activity Affirmed in Microsatellite Instability-High mCRC

January 24th 2017

The promising antitumor activity of nivolumab in patients with microsatellite instability-high metastatic colorectal cancer was sustained in an update of the phase II CheckMate-142 trial.

Trend Toward Better PFS With Four-Drug CRC Regimen

January 24th 2017

Patients with advanced colorectal cancer had a modest gain in progression-free survival with the addition of irinotecan to standard chemotherapy plus an angiogenesis inhibitor as induction therapy, a randomized trial showed.

Dr. Muro on Results of PaFF-K Study in Colorectal Cancer

January 23rd 2017

Kei Muro, MD, Aichi Cancer Center Hospital, discusses the results of the PaFF-K study in metastatic colorectal cancer.

Dr. Loaiza-Bonilla on Differences in Mutation Rates Between Right- and Left-Sided CRC

January 22nd 2017

Arturo Loaiza-Bonilla, MD, medical oncologist, the University of Pennsylvania, discusses a study investigating differences in mutation rates between right- and left-sided colorectal cancer.

Dr. Overman Discusses Updated Findings of CheckMate-142 in Patients With MSI-H mCRC

January 20th 2017

Michael J. Overman, MD, medical oncologist, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses updated results from the CheckMate 142 trial, which investigated nivolumab (Opdivo) alone or in combination with ipilimumab (Yervoy) in patients with DNA mismatch repair deficient/microsatellite instability high (MSI-H) metastatic colorectal cancer (mCRC).

Watch-and-Wait Approach a Potential Option for Patients With Rectal Cancer

January 18th 2017

A watch-and-wait approach is emerging as a potential treatment strategy for patients with rectal cancer.

Analysis Shows Link Between Daily Physical Activity and Improved mCRC Outcomes

January 18th 2017

Patients with metastatic colorectal cancer who engaged in daily moderate physical activity demonstrated a reduction in mortality and cancer progression.

Individualized Treatment Needed for Patients With NRAS-Mutated mCRC

January 15th 2017

Activating, hotspot mutations in the NRAS gene occur in a small subset of patients with metastatic colorectal cancer. These mutations are now being identified in routine clinical practice by extended RAS genotyping.

Dr. Pietrantonio on Survival Rates in Colorectal Cancer

January 14th 2017

Filippo Pietrantonio, MD, Department of Medical Oncology, Medical Oncology Unit, Milan Fondazione IRCCS Istituto Nazionale dei Tumori, discusses survival rates in patients with colorectal cancer.

Dr. Bekaii Saab on Immunotherapeutic Options in CRC Beyond PD-1/PD-L1

January 12th 2017

Tanios Bekaii-Saab, MD, professor of Medicine, Mayo Clinic, discusses immunotherapeutic options being explored in the treatment landscape of colorectal cancer (CRC) beyond PD-1/PD-L1 agents.

Dr. Venook on Advice for Oncologists Treating Patients With CRC

January 9th 2017

Alan P. Venook, MD, The Madden Family Distinguished Professor of Medical Oncology and Translational Research at the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, provides advice to community oncologists who are treating patients with colorectal cancer.